Search

Your search keyword '"Thaker, Premal H"' showing total 907 results

Search Constraints

Start Over You searched for: Author "Thaker, Premal H" Remove constraint Author: "Thaker, Premal H"
907 results on '"Thaker, Premal H"'

Search Results

108. Endometrial Cancer Surveillance Counterpoint: USA

110. High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancer

112. Assessment of quality improvement priorities to improve care delivery for patients with ovarian cancer.

118. Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival.

119. NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

121. Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography

127. Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: Relationships with depression, fatigue, and disability

130. Reply

131. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

134. Abstract 2429: Tumor and stromal AXL expression regulate ovarian cancer metastasis

136. Genomic analysis of clear cell carcinoma.

139. Exploring the nuances between BRCA1 and 2: A multiomic analysis.

141. GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

145. GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress

148. Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer

149. Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations

150. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer

Catalog

Books, media, physical & digital resources